腹腔热灌注化疗联合免疫治疗在恶性腹水中的应用  

The clinical applications of HIPEC plus immunotherapy in the malignant ascites

作　　者：王俞[1] 崔书中[1] 巴明臣[1] 

机构地区：[1]广州医科大学附属肿瘤医院腹外二科暨体腔热灌注治疗中心,广州510095

出　　处：《临床肿瘤学杂志》2013年第11期1041-1044,共4页Chinese Clinical Oncology

基　　金：广州市科技局基金资助项目(2010GN-E00221);广州医科大学博士启动基金资助项目(2012C66)

摘　　要：腹腔热灌注化疗(HIPEC)作为治疗进展期胃癌、结直肠癌及卵巢癌等腹腔肿瘤合并恶性腹水的有效措施,已广泛应用于临床。有国内外学者对腹腔肿瘤合并恶性腹水患者行HIPEC后,再辅以免疫治疗(腹腔内常温灌注白介素-2、干扰素等免疫制剂),收到了更好的临床疗效,提示HIPEC联合免疫治疗是一种更为科学的综合治疗方法。本文旨在对HIPEC联合免疫治疗在恶性腹水中的应用研究进展作一综述。Hyperthermic intraperitoneal chemotherapy （HIPEC）, a promising treatment modality for advanced gastric cancer, colorectal cancer, ovarian cancer and other abdominal malignant tumors with ascites, has been widely used in the clinic. The HIPEC sup- plemented by immunotherapy with intraperitoneal perfusion of interleukin-2, interferon and other immune agents appears to be a feasible and effective treatment for malignant ascites. The combination of HIPEC and immunotherapy can be regarded as a scientific and compre- hensive treatment. This review will focus on the clinical applications of HIPEC plus immunotherapy for the treatment of malignant ascites.

关 键 词：腹腔热灌注化疗 恶性腹水 免疫治疗 

分 类 号：R735.7[医药卫生—肿瘤]